CG Oncology Expands At-The-Market Equity Offering Capacity

CG Oncology, Inc. ( (CGON) ) has provided an update.

On January 13, 2026, CG Oncology, Inc. filed an amended prospectus with the U.S. Securities and Exchange Commission to expand its existing open market stock offering program with Jefferies LLC, increasing the total aggregate offering capacity from $250 million to up to $550 million of common stock. The company had previously sold 5,861,984 shares for gross proceeds of $250 million under this sales agreement and is now seeking to raise an additional $300 million, a move that significantly enlarges its potential capital-raising runway and could support future corporate financing needs and strategic initiatives while diluting existing shareholders if fully utilized.

The most recent analyst rating on (CGON) stock is a Buy with a $82.00 price target. To see the full list of analyst forecasts on CG Oncology, Inc. stock, see the CGON Stock Forecast page.

Spark’s Take on CGON Stock

According to Spark, TipRanks’ AI Analyst, CGON is a Neutral.

The score is primarily driven by mixed financial performance: a very strong, low-debt balance sheet is outweighed by heavy losses and ongoing cash burn. Technicals are modestly supportive with neutral-to-positive momentum and price above key moving averages. Valuation is pressured by negative earnings and no dividend, while the accelerated Phase 3 timeline is a meaningful positive catalyst but secondary to current fundamentals.

To see Spark’s full report on CGON stock, click here.

More about CG Oncology, Inc.

CG Oncology, Inc. is a publicly traded biotechnology company that issues common stock to fund its operations and growth, accessing capital markets through open market sale agreements with investment banks such as Jefferies LLC.

Average Trading Volume: 1,005,334

Technical Sentiment Signal: Buy

Current Market Cap: $4.37B

For a thorough assessment of CGON stock, go to TipRanks’ Stock Analysis page.